Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Welcome and Introduction to Vi3C

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Mar
23
Today In Oncology
Black Race Predicts Inferior Survival in AML Independent of Cytogenetic Risk
Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
The Thymus Plays a Part in Adult Cancer Risk and Treatment Response
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo